Statera Biopharma, Inc.
STAB
$0.00
$0.000.00%
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | 508.58% | -- | 273.62% | 273.62% | 273.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,459.24% | -- | 3,825.43% | 2,249.13% | 273.62% |
| Cost of Revenue | 845.99% | -- | -- | -- | -- |
| Gross Profit | 2,048.67% | -- | -- | -- | -- |
| SG&A Expenses | -21.77% | 39.71% | 122.00% | 307.20% | 298.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.11% | 54.04% | 127.97% | 217.84% | 162.36% |
| Operating Income | 13.94% | -38.62% | -111.71% | -203.26% | -159.86% |
| Income Before Tax | -218.34% | -364.37% | -523.64% | -742.38% | -185.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -218.34% | -364.37% | -523.64% | -742.38% | -185.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 85.82% | -- | -- | -- | -- |
| Net Income | -218.40% | -364.23% | -523.47% | -742.17% | -185.71% |
| EBIT | 13.94% | -38.62% | -111.71% | -203.26% | -159.86% |
| EBITDA | 15.71% | -92.60% | -271.88% | -800.57% | -- |
| EPS Basic | -62.81% | 1.75% | -10.60% | -19.29% | 30.77% |
| Normalized Basic EPS | 63.30% | 70.79% | 61.68% | 58.18% | 38.66% |
| EPS Diluted | -62.81% | 1.75% | -10.60% | -19.29% | 30.77% |
| Normalized Diluted EPS | 63.30% | 70.79% | 61.68% | 58.18% | 38.66% |
| Average Basic Shares Outstanding | 105.07% | 147.90% | 161.97% | 153.81% | 51.53% |
| Average Diluted Shares Outstanding | 105.07% | 147.90% | 161.97% | 153.81% | 51.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |